Search results
Dec 12, 2022 · In the complete 2023 Standards of Care, see recommendations 14.67–14.73 for guidance on the pharmacologic management of type 2 diabetes in youth and Tables 14.1A and 14.1B for screening and treatment recommendations for type 1 and type 2 diabetes in youth.
The 2024 Standards of Care in Diabetes includes all of ADA's current clinical practice recommendations and is intended to provide clinicians, patients, researchers, payers, and others with the components of diabetes care, general treatment goals, and tools to evaluate the quality of care.
The Standards of Care in Diabetes (Standards of Care) includes all of current clinical practice recommendations of the American Diabetes Association (ADA) and is intended to provide clinicians, researchers, policy makers, and other individuals with the components of diabetes care, general treatment goals, and tools to evaluate the quality of care.
Dec 12, 2022 · American Diabetes Association® (ADA) published Standards of Care in Diabetes—2023 (Standards of Care), comprehensive, evidence-based guidelines for the prevention, diagnosis, and treatment of diabetes.
Jan 1, 2022 · In the complete 2022 Standards of Care, see recommendations 14.67–14.73 for detailed guidance on pharmacologic management of type 2 diabetes in youth and Tables 14.1A and 14.1B for screening and treatment recommendations for type 1 and type 2 diabetes in youth.
Jan 1, 2021 · See Figure 9.1 for general recommendations regarding glucose-lowering treatment for adults with type 2 diabetes and Table 9.1 for patient- and drug-specific factors to consider when selecting glucose-lowering agents.
Dec 9, 2020 · The Standards of Medical Care in Diabetes—2021 provides the latest in comprehensive, evidence-based recommendations for the diagnosis and treatment of children and adults with type 1, type 2, or gestational diabetes; strategies for the prevention or delay of type 2 diabetes; and therapeutic approaches that can reduce complications, mitigate ...
Dec 11, 2023 · More guidance on the use of new obesity medications, glucagon-like peptide 1 (GLP-1) agonists or dual glucose-dependent insulinotropic polypeptide (GIP) receptor agonists, to reach sustained weight management goals. Updates in guidance on the diagnosis and classification of diabetes . A focus on hypoglycemia prevention and management .
The 2020 algorithm for management of persons with type 2 diabetes includes sections on lifestyle therapy, a complications-centric model for care of persons with overweight/obesity, prediabetes, management of hypertension and dyslipidemia (risk factors for atherosclerotic cardiovascular disease), glucose control with medications, insulin therapy,...
Feb 28, 2022 · Some of the important updates include treatment algorithms emphasizing comorbid conditions such as atherosclerotic cardiovascular disease, heart failure, and chronic kidney disease in the selection of anti-diabetic agents; wider application of continuous glucose monitoring (CGM), insulin pump technologies and indices derived from CGM such as tim...
